28 results
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
12 Sep 23
Other Events
7:00am
identify neurodegeneration targets and treatments. NIH and Advocacy groups help us cost - effectively develop clinical candidates. What we offer … Targets oligomers, a pathogenic form of amyloid plaques produced early in AD Blocks toxic oligomer binding, displaces bound oligomers - protecting
S-1/A
EX-10.21
CGTX
Cognition Therapeutics Inc
29 Jul 21
IPO registration (amended)
4:45pm
, development, marketing, manufacturing, sale or other commercialization of any compound or other agent that targets the sigma-2/PGRMC 1 receptor
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
24 Aug 23
Regulation FD Disclosure
7:00am
developed programs with pharma interest in mind. The What: Our Pittsburgh Labs were formed to identify specific neurodegeneration targets. The result
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
4 Jan 24
Other Events
4:21pm
that targets Aβ oligomers and α-synuclein oligomers Appx 50% of DLB patients have both Aβ and α-synuclein oligomers present By regulating cellular
DRS
EX-10.14
4d6a8p
7 May 21
Draft registration statement
12:00am
S-1
EX-10.15
k38bydtj2dhyicxyi
19 Jul 21
IPO registration
7:02am
S-1/A
EX-10.16
pp04zc6b
29 Jul 21
IPO registration (amended)
4:45pm
DRS
rdpwo18a2z8r p0
7 May 21
Draft registration statement
12:00am
DEF 14A
iw9bb
25 Apr 22
Definitive proxy
5:28pm
10-Q
ky80l 47g1
17 Nov 21
Quarterly report
5:15pm